



Complete Summary

GUIDELINE TITLE

Clinical guideline on dental management of pediatric patients receiving chemotherapy, hematopoietic cell transplantation, and/or radiation.

BIBLIOGRAPHIC SOURCE(S)

American Academy of Pediatric Dentistry. Clinical guideline on dental management of pediatric patients receiving chemotherapy, hematopoietic cell transplantation, and/or radiation. Chicago (IL): American Academy of Pediatric Dentistry; 2004. 6 p. [24 references]

GUIDELINE STATUS

This is the current release of the guideline.

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

- Oral and dental problems
- Cancer

GUIDELINE CATEGORY

Diagnosis
Management
Prevention
Treatment

CLINICAL SPECIALTY

Dentistry
Oncology
Pediatrics

INTENDED USERS

Dentists
Nurses
Physicians

GUIDELINE OBJECTIVE(S)

- To provide clinical guidelines on the dental management of pediatric patients receiving chemotherapy, hematopoietic cell transplantation (HCT), and/or radiation
- To provide guidelines on the diagnosis, prevention, stabilization, and treatment of oral and dental problems that can compromise the child's quality of life before, during, and after the cancer treatment

TARGET POPULATION

Pediatric patients receiving chemotherapy, hematopoietic cell transplantation, and/or radiation

INTERVENTIONS AND PRACTICES CONSIDERED

Dental and Oral Care before the Initiation of Cancer Therapy

1. Obtain medical history including:
 - Type of cancer
 - Treatment protocol
 - Medications
 - Allergies
 - Immunosuppression status
 - For hematopoietic cell transplantation (HCT) patients, include type of transplant, conditioning protocol, and graft versus host disease (GVHD) prophylaxis
2. Dental history review
3. Oral dental assessment
4. Preventive strategies:
 - Oral hygiene (brushing, chlorhexidine rinse)
 - Encouraging non-cariogenic diet and advising on cariogenic potential of supplements
 - Use of fluoride (toothpaste, supplements, gels/rinses, varnish)
 - Trismus prevention/treatment
 - Reduction of radiation to healthy oral tissues
 - Use of lead-lined stents, prostheses, and shields
 - Use of beam-sparing procedures
 - Education of patient/caretaker on optimal oral care and the possible acute and long-term effects of the therapy in the craniofacial complex
5. Hematological considerations in dental care

- Use of antibiotic therapy for low absolute neutrophil count (ANC)
 - Platelet transfusions for low platelet count
 - Other coagulation tests
6. Dental procedures
- Timing of and prioritizing procedures in relation to cancer therapy
 - Pulp therapy in primary teeth
 - Endodontic treatment in permanent teeth (root canal or extraction)
 - Use of orthodontic appliances and space maintainers
 - Excision of overlying gingival tissue
 - Extractions

Dental and Oral Care during Immunosuppression Periods

1. Preventive strategies
 - Oral hygiene (use of soft nylon or foam brushes, chlorhexidine-soaked brushes, electric or ultrasonic brushes, flossing)
 - Encouraging non-cariogenic diet and advising on cariogenic potential of supplements
 - Use of fluoride (toothpaste, supplements, gels/rinses, varnish)
 - Lip care (lanolin-based creams and ointments)
 - Education of patient/caretaker on optimal oral care and the possible acute and long-term effects of the therapy in the craniofacial complex
2. Conservative emergency dental care only
3. Management of oral conditions related to cancer therapies, including mucositis, oral mucosal infections, oral bleeding, dental sensitivity/pain, and xerostomia

Dental and Oral Care after the Cancer Therapy is Completed (Exclusive of HCT)

1. Preventive strategies
 - Oral hygiene (normal brushing and flossing, air-drying of brushes)
 - Encouraging non-cariogenic diet and advising on cariogenic potential of supplements
 - Use of fluoride (toothpaste, supplements, gels/rinses, varnish)
 - Lip care (lanolin based creams and ointments)
 - Education of patient/caretaker on optimal oral care and the possible acute and long-term effects of the therapy in the craniofacial complex
2. Dental care
 - Periodic evaluation
 - Orthodontic treatment (starting or resuming orthodontic care after completion of all therapy and after at least 2-year disease-free survival)
 - Use of appliances that minimize the risk of root resorption
 - Use of lighter forces
 - Terminating treatment earlier than normal
 - Choosing the simplest method for the treatment needs
 - Not treating the lower jaw
 - Oral surgical procedures (use of pre-operative hyperbaric oxygen in patients with prior cranial radiation therapy)

HCT

1. Phase I (Pre-transplantation): Completion of all dental treatment before the child is admitted
2. Phase II (Conditioning/neutropenia): Following patient closely during the hospitalization period to monitor and treat oral changes and reinforce the importance of optimal oral care
3. Phase III (Initial engraftment of hematopoietic reconstitution):
 - Performing dental/oral examination
 - Performing dental cleaning and soft tissue curettage (only if authorized by the HCT team)
 - Encouraging patient to continue optimal oral hygiene and avoid a cariogenic diet
 - Assessing xerostomia symptoms and compliance with GVHD treatment
4. Phase IV (Immune reconstitution/late post-transplantation):
 - Scheduling regular dental examination with radiographs
 - Avoiding invasive dental treatments in patients with profound impairment of immune function

MAJOR OUTCOMES CONSIDERED

Not stated

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

This guideline is based on a review of the current dental and medical literature related to dental management of pediatric patients receiving chemotherapy, hematopoietic cell transplantation, and/or radiation. A MEDLINE search was conducted using the terms "pediatric cancer," "pediatric oncology," "hematopoietic cell transplantation," "bone marrow transplantation," "mucositis," "stomatitis," "chemotherapy," "radiation therapy," "acute effects," "long-term effects," "dental care," "pediatric dentistry," and "clinical practice guidelines."

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

The oral health policies and clinical guidelines of the American Academy of Pediatric Dentistry (AAPD) are developed under the direction of the Board of Trustees, utilizing the resources and expertise of its membership operating through the Council on Clinical Affairs (CCA).

Proposals to develop or modify policies and guidelines may originate from 4 sources:

1. the officers or trustees acting at any meeting of the Board of Trustees
2. a council, committee, or task force in its report to the Board of Trustees
3. any member of the AAPD acting through the Reference Committee hearing of the General Assembly at the Annual Session
4. officers, trustees, council and committee chairs, or other participants at the AAPD's Annual Strategic Planning Session

Regardless of the source, proposals are considered carefully, and those deemed sufficiently meritorious by a majority vote of the Board of Trustees are referred to the CCA for development or review/revision.

Once a charge (directive from the Board of Trustees) for development or review/revision of an oral health policy or clinical guideline is sent to the CCA, it is assigned to 1 or more members of the CCA for completion. CCA members are instructed to follow the specified format for a policy or guideline. All oral health policies and clinical guidelines are based on 2 sources of evidence: (1) the scientific literature; and (2) experts in the field. Members may call upon any expert as a consultant to the council to provide expert opinion. The Council on Scientific Affairs provides input as to the scientific validity of a policy or guideline.

The CCA meets on an interim basis (midwinter) to discuss proposed oral health policies and clinical guidelines. Each new or reviewed/revise policy and guideline is reviewed, discussed, and confirmed by the entire council.

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Once developed by the Council on Clinical Affairs (CCA), the proposed policy or guideline is submitted for the consideration of the Board of Trustees. While the board may request revision, in which case it is returned to the council for modification, once accepted by majority vote of the board, it is referred for Reference Committee hearing at the upcoming Annual Session. At the Reference Committee hearing, the membership may provide comment or suggestion for alteration of the document before presentation to the General Assembly. The final document then is presented for ratification by a majority vote of the membership present and voting at the General Assembly. If accepted by the General Assembly, either as proposed or as amended by that body, the document then becomes the official American Academy of Pediatric Dentistry (AAPD) oral health policy or clinical guideline for publication in the AAPD's Reference Manual and on the AAPD's Web site.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Dental and Oral Care before the Initiation of Cancer Therapy

Objectives: The objectives of a dental/oral examination before cancer therapy starts are two-fold:

1. To identify and stabilize or eliminate existing and potential sources of infection, local irritants, and irregular surfaces that may complicate the cancer therapy and hematopoietic cell transplantation (HCT) without needlessly delaying the cancer treatment or inducing complications; and
2. To educate the patient and caretakers about the importance of optimal oral care in order to minimize oral problems/discomfort during and after treatment and about the possible acute and long-term effects of the therapy in the craniofacial complex

Initial Evaluation

Medical history review should include, but not be limited to, type of cancer, treatment protocol, medications, allergies, and immunosuppression status. For HCT patients, include type of transplant, conditioning protocol, and graft versus host disease (GVHD) prophylaxis. The presence of an indwelling venous catheter (i.e., central line) dictates the need for endocarditis prophylaxis following the

American Heart Association (AHA) recommendations; however, this recommendation is empirical.

Dental history review includes information such as habits, trauma, symptomatic teeth, previous care, preventive practices, etc.

Oral/dental assessment should include thorough head, neck, and intraoral examinations, oral hygiene assessment and training, and radiographic evaluation based on history and clinical findings.

Preventive Strategies

Oral hygiene: Oral hygiene includes brushing of the teeth and tongue 2 to 3 times daily with regular soft brush or electric toothbrush, regardless of the hematological status. Ultrasonic brushes and dental floss should be allowed only if the patient is properly trained. Patients with poor oral hygiene and/or periodontal disease can use chlorhexidine rinses daily until the tissue health improves or mucositis starts. The high alcohol content can cause discomfort and dehydrate the tissues.

Diet: Dental practitioners should encourage a non-cariogenic diet and advise caretakers about the high cariogenic potential of dietary supplements rich in carbohydrate and oral pediatric medications rich in sucrose.

Fluoride: Preventive measures include the use of fluoridated toothpaste, fluoride supplements if indicated, neutral fluoride gels/rinses, or applications of fluoride varnish for patients at risk for caries and/or xerostomia. A brush-on technique is the most convenient technique making patients more compliant.

Trismus prevention/treatment: Patients who receive radiation therapy to the masticatory muscles may develop trismus. Thus, daily stretching oral exercises/physical therapy should start before radiation is initiated and continue throughout treatment. Therapy also may include prosthetic aids to reduce the severity of fibrosis, trigger-point injections, analgesics, muscle-relaxants, and other pain management strategies.

Reduction of radiation to healthy oral tissues: In cases of radiation to the head and neck, the use of lead-lined stents, prostheses, and shields, as well as beam-sparing procedures, should be discussed with the radiation oncologist.

Education: Patient/caretaker education includes the importance of optimal oral care in order to minimize oral problems/discomfort during and after treatment and the possible acute and long-term effects of the therapy in the craniofacial complex.

Dental Care

Hematological Considerations

1. Absolute neutrophil count (ANC)

- $>1,000/\text{mm}^3$: no need for antibiotic prophylaxis. However, some authors suggest that antibiotic coverage (AHA recommendations) may be prescribed when the ANC is between 1,000 and 2,000/ mm^3 . If infection is present or unclear, more aggressive antibiotic therapy may be indicated and should be discussed with the medical team.
 - $<1,000/\text{mm}^3$: defer elective dental care until the ANC rises. In dental emergency cases, discuss antibiotic coverage beyond endocarditis prophylaxis with medical team before proceeding with treatment. The patient may need hospitalization for dental management.
2. Platelet count
 - $>75,000/\text{mm}^3$: no additional support needed but be prepared to treat prolonged bleeding by using sutures, hemostatic agents, pressure packs, gelatin foams, etc.
 - 40,000-75,000/ mm^3 : platelet transfusions may be considered pre- and 24 hours post-operatively
 - $<40,000/\text{mm}^3$: defer care. In dental emergency cases, contact physician before proceeding. Consider platelet transfusion and hospital admission for treatment.
 3. Other coagulation tests may be in order for individual patients.

Dental Procedures

1. In general terms, most oncology/hematology protocols (exclusive of HCT, which will be discussed later) are divided into phases (cycles) of chemotherapy, in addition to other therapies (radiotherapy, surgery, etc). The patient's blood counts normally start falling 5 to 7 days after the beginning of each cycle, staying low for approximately 14-21 days, before rising again to normal levels for a few days until the next cycle begins. Ideally, all dental care should be completed before cancer therapy is initiated. But, when that is not feasible, temporary restorations can be placed and non-acute dental treatment can be delayed until the patient's hematological status is stable, usually in the few days between treatment cycles.
2. Prioritizing procedures: When all dental needs cannot be treated before cancer therapy is initiated, priorities should be infections, extractions, periodontal care (scaling, prophylaxis), and sources of tissue irritation before the treatment of carious teeth, root canal therapy for permanent teeth, and replacement of faulty restorations. The risk for pulpal infection and pain determine which carious lesions should be treated first. Incipient to small caries can be treated with fluorides and sealants until definitive care can be accomplished. It is also important to be aware that the signs and symptoms of periodontal disease can be decreased in immunosuppressed patients.
3. Pulp therapy in primary teeth: Although there have been no studies to date that address the safety of performing pulp therapy in primary teeth prior to the initiation of chemotherapy and/or radiotherapy, many clinicians choose to provide a more radical treatment in the form of extraction because pulpal/periapical/furcal infections during immunosuppression periods can have a significant impact on cancer treatment and become life-threatening. Teeth that already have been treated pulpally and are clinically and radiographically sound present minimal risk.
4. Endodontic treatment in permanent teeth: Symptomatic non-vital permanent teeth should receive root canal treatment at least 1 week before initiation of cancer therapy to allow sufficient time to assess treatment success before the

- chemotherapy. If that is not possible, extraction is indicated. Extraction is also the treatment of choice for teeth that cannot be treated by definitive endodontic treatment in a single visit. In that case, the extraction should be followed by antibiotic therapy (penicillin or for penicillin-allergic patients, clindamycin) for about 1 week. Asymptomatic endodontic needs in permanent teeth can be delayed until the hematological status of the patient is stable. It is important that the etiology of periapical lesions associated with previously endodontically treated teeth be determined because they can be caused by a number of factors including pulpal infections, inflammatory reactions, apical scars, cysts, and malignant lesions. If a periapical lesion is associated with an endodontically treated tooth and no signs or symptoms of infection are present, there is no need for retreatment or extraction since the radiolucency is likely due to an apical scar.
5. Orthodontic appliances and space maintainers: Appliances should be removed if the patient has poor oral hygiene and/or the treatment protocol or HCT conditioning regimen carries a risk for the development of moderate to severe mucositis, except for smooth appliances such as band and loops and fixed lower lingual arches. Removable appliances and retainers that fit well may be worn as long as tolerated by the patient who shows good oral care. If band removal is not possible, vinyl mouth guards or orthodontic wax should be used to decrease tissue trauma.
 6. Periodontal considerations: Partially erupted molars can become a source of infection because of pericoronitis. The overlying gingival tissue should be excised if the dentist believes it is a potential risk and if the hematological status permits.
 7. Extractions: There are no clear recommendations for the use of prophylactic antibiotics for extractions. Recommendations generally have been empiric or based on anecdotal experience. Particular attention should be given to extraction of permanent teeth in patients who will receive or have received radiation to the face because of the risk of osteoradionecrosis. Surgical procedures must be as atraumatic as possible, with no sharp bony edges remaining and satisfactory closure of the wounds. If there is documented infection associated with the tooth, antibiotics, ideally chosen with the benefit of sensitivity testing, should be administered for about 1 week.
 - Loose primary teeth should be left to exfoliate naturally and the patient should be counseled to not play with them in order to avoid bacteremia. If the patient cannot comply with this recommendation, the teeth should be removed if the hematologic parameters allow.
 - Impacted teeth, root tips, teeth with periodontal pockets >6 mm, teeth exhibiting acute infections, significant bone loss, involvement of the furcation, or mobility, and non-restorable teeth should be removed ideally 2 weeks (or at least 7 to 10 days) before cancer therapy starts to allow adequate healing.
 - Some practitioners prefer to extract all third molars that are not fully erupted, particularly prior to HCT, while others favor a more conservative approach, recommending extraction of third molars at risk for pulpal infection or those associated with significant periodontal infection, including pericoronitis.
 - If a permanent tooth cannot be extracted for medical reasons (i.e., severe thrombocytopenia), then the crown should be amputated above the gingiva and root canal therapy should be initiated on the remaining root fragment to minimize the risk of disseminating infection through the systemic circulation. The root canal chamber should be sealed with

an antimicrobial medicament. Antibiotics should follow for 7 to 10 days afterwards with the extraction subsequently done when the patient's hematological status is normal.

Dental and Oral Care during Immunosuppression Periods

Objectives: The objectives of a dental/oral care during cancer therapy are three-fold:

1. To maintain optimal oral health during cancer therapy;
2. To manage any oral side effects that may develop as a consequence of the cancer therapy; and
3. To educate the patient and caretakers about the importance of optimal oral care in order to minimize oral problems/discomfort during treatment

Preventive Strategies

Oral hygiene: Intensive oral care is of paramount importance because it reduces the risk of developing moderate/severe mucositis without causing an increase in septicemia and infections in the oral cavity. Thrombocytopenia should not be the sole determinant of oral hygiene as patients are able to brush without bleeding at widely different levels of platelet count. Patients should use a soft nylon brush 2 to 3 times daily. Fluoridated toothpaste can be used, but if the patient does not tolerate it during periods of mucositis, it can be discontinued and water or saline solution can be substituted. If moderate to severe mucositis develops and the patient cannot tolerate a regular toothbrush or an endtufted brush, foam brushes or super soft brushes soaked in aqueous chlorhexidine can be used, although they do not provide efficient cleaning. The use of a regular brush should be resumed as soon as the mucositis improves.

Brushes should be air-dried between uses. Electric or ultrasonic brushes are acceptable if the patient is capable of using them without causing trauma and irritation. If patients are skilled at flossing without traumatizing the tissues, it is reasonable to continue flossing throughout treatment. Toothpicks and water irrigation devices should be avoided when the patient is pancytopenic.

Diet: Dental practitioners should encourage a non-cariogenic diet and advise caretakers about the high cariogenic potential of dietary supplements rich in carbohydrate and oral pediatric medications rich in sucrose.

Fluoride: Preventive measures include the use of fluoridated toothpaste, fluoride supplements if indicated, neutral fluoride gels/rinses, or applications of fluoride varnish for patients at risk for caries and/or xerostomia. A brush-on technique is the most convenient technique making patients more compliant.

Lip care: Lanolin-based creams and ointments are more effective in moisturizing and protecting against damage than petrolatum-based products.

Education: Patient/caretaker education includes the importance of optimal oral care in order to minimize oral problems/discomfort during treatment and the possible acute and long-term effects of the therapy in the craniofacial complex.

Dental Care

Only conservative emergency dental care should be provided during immunosuppression, and only after consultation with the medical team in regards to platelet and antibiotic therapy. Patients who are using plant alkaloid chemotherapeutic agents (vincristine, vinblastine) may present deep, constant pain (mostly in the mandible) in the absence of odontogenic pathology. The pain resolves with discontinuation of the drugs and no treatment is necessary. The patient should be seen not less often than every 6 months for an oral health evaluation during treatment, preferably in times of stable hematological status and always after reviewing the medical history and the need for endocarditis coverage if a central line is still in place.

Management of Oral Conditions Related to Cancer Therapies

Mucositis: Mucositis care remains focused on palliation of symptoms and efforts to reduce the influence of secondary factors on mucositis. The International Society for Oral Oncology has published guidelines for treatment of mucositis. Most studies do not demonstrate a prophylactic impact of chlorhexidine on mucositis.

Oral mucosal infections: The signs of inflammation and infection may be greatly diminished during neutropenic periods. Thus, the clinical appearance of infections may differ significantly from the normal. Close monitoring of the oral cavity allows for timely diagnosis and treatment of fungal, viral, and bacterial infections. Prophylaxis with nystatin for fungal infections is not effective. Oral cultures and/or biopsies of all suspicious lesions should be done and prophylactic medications should be initiated until more specific therapy can be prescribed.

Oral bleeding: Oral bleeding occurs due to thrombocytopenia, disturbance of coagulation factors, and damaged vascular integrity. Treatment should consist of local approaches (pressure packs, anti-fibrinolytic rinses, gelatin sponges, etc) and systemic measures (platelet transfusions).

Dental sensitivity/pain: Tooth sensitivity could be related to decreased secretion of saliva during radiation therapy and the lowered salivary pH.

Xerostomia: Sugar-free chewing gum, candy, sucking tablets, special dentifrices for oral dryness, saliva substitutes, frequent sipping of water, bland oral rinses, and/or oral moisturizers are recommended. Saliva stimulating drugs are not approved for use in children. Fluoride rinses and gels are recommended highly for caries prevention.

Dental and Oral Care after the Cancer Therapy is Completed (Exclusive of HCT)

Objectives: The objectives of a dental/oral examination after cancer therapy ends are two-fold:

1. To maintain optimal oral health; and
2. To educate the patient and caretakers about the importance of optimal oral care in order to minimize oral problems/discomfort after treatment and about

the possible acute and long-term effects of the therapy in the craniofacial complex

Preventive Strategies

Oral hygiene: Patients should resume normal tooth brushing 2 to 3 times daily. Brushes should be air-dried between uses. Patients should continue/resume daily flossing.

Diet: Dental practitioners should encourage a non-cariogenic diet and advise caretakers about the high cariogenic potential of dietary supplements rich in carbohydrate and oral pediatric medications rich in sucrose.

Fluoride: Preventive measures include the use of fluoridated toothpaste, fluoride supplements if indicated, neutral fluoride gels/rinses, or applications of fluoride varnish for patients at risk for caries and/or xerostomia. A brush-on technique is the most convenient technique making patients more compliant.

Lip care: Lanolin-based creams and ointments are more effective in moisturizing and protecting against damage than petrolatum-based products.

Education: Patient/caretaker education includes the importance of optimal oral care in order to minimize oral problems/discomfort after treatment and the possible acute and long-term effects of the therapy in the craniofacial complex.

Dental Care

Periodic evaluation: The patient should be seen at least every 6 months (sooner if more imperative issues such as xerostomia and trismus are present). Patients who have experienced chronic or severe mucositis should be followed closely for malignant transformation of their oral mucosa (e.g., oral squamous cell carcinoma).

Orthodontic treatment: Orthodontic care may start or resume after completion of all therapy and after at least a 2 year disease-free survival when the risk of relapse is decreased and the patient is no longer using immunosuppressive drugs. A thorough assessment of any dental developmental disturbances caused by the cancer therapy must be done before initiating orthodontic treatment. The following strategies should be considered to provide orthodontic care for patients with dental sequelae: (1) use appliances that minimize the risk of root resorption, (2) use lighter forces, (3) terminate treatment earlier than normal, (4) choose the simplest method for the treatment needs, and (5) do not treat the lower jaw. However, specific guidelines for orthodontic management, including optimal force and pace, remain undefined.

Oral surgical procedures such as an extraction or excisional biopsy may require pre-operative and post-operative hyperbaric oxygen to avoid osteomyelitis if the patient has had previous cranial radiation therapy to the involved maxillary or mandibular area.

Hematopoietic Cell Transplantation

Specific oral complications can be correlated with phases of HCT.

Phase I: Pre-Transplantation

The oral complications are related to the current systemic and oral health, oral manifestations of the underlying condition, and oral complications of recent medical therapy.

Dental and oral care before the transplant: Most of the principles are similar to those discussed for pediatric cancer. The 2 major differences are: 1) in HCT, the patient receives all the chemotherapy and/or total body irradiation in just a few days before the transplant, and 2) there will be prolonged immunosuppression following the transplant. Elective dentistry will need to be postponed until immunological recovery has occurred, which may take as long as 9 to 12 months after HCT, or longer if chronic GVHD or other complications are present. Therefore, all dental treatment must be completed before the child is admitted in order to eliminate disease that could lead to complications during and after the transplant.

Phase II: Conditioning/Neutropenia

The oral complications are related to the conditioning regimen and medical therapies, approximately to day 30 post-transplant. Mucositis, xerostomia, oral pain, oral bleeding, opportunistic infections, and taste dysfunction can be seen. The patient should be followed up closely during the hospitalization period to monitor and treat the oral changes and reinforce the importance of optimal oral care. Dental care usually is not allowed in this phase.

Phase III: Initial Engraftment to Hematopoietic Reconstitution

The intensity and severity of complications begin to decrease normally 3 to 4 weeks after transplantation. Oral fungal infections and herpes simplex virus infection are most notable. Oral GVHD can become a concern for allogeneic graft recipients. A dental/oral examination should be performed and invasive dental procedures, including dental cleanings and soft tissue curettage, should be done only if authorized by the HCT team because of the patient's continued immunosuppression. Patients should be encouraged to continue optimal oral hygiene and avoid a cariogenic diet. Attention to xerostomia and oral GVHD treatment, including topical application of steroids or cyclosporine, and oral psoralen and ultraviolet A therapy, are a must. HCT patients are particularly sensitive to thermal stimuli between 2 and 4 months post-transplant. Topical application of neutral fluoride helps reduce the sensitivity.

Phase IV: Immune Reconstitution/Late Post-Transplantation

After day 100 post-HCT, the oral complications predominantly are related to the chronic toxicity associated with the conditioning regimen, including salivary dysfunction, craniofacial growth abnormalities, late viral infections, oral chronic GVHD, and oral squamous cell carcinoma. Regular dental examinations with radiographs can be done routinely, but invasive dental treatment should be

avoided in patients with profound impairment of immune function. Orthodontic treatment considerations are the same as discussed in the previous section.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

All oral health policies and clinical guidelines are based on 2 sources of evidence: (1) the scientific literature; and (2) experts in the field.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

The most frequently documented source of sepsis in the immunosuppressed cancer patient is in the mouth; therefore, early and radical dental intervention, including aggressive oral hygiene measures, reduces the risk for oral and associated systemic complications.

POTENTIAL HARMS

Not stated

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Chart Documentation/Checklists/Forms
Resources

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Living with Illness
Staying Healthy

IOM DOMAIN

Effectiveness
Patient-centeredness

IDENTIFYING INFORMATION AND AVAILABILITY**BIBLIOGRAPHIC SOURCE(S)**

American Academy of Pediatric Dentistry. Clinical guideline on dental management of pediatric patients receiving chemotherapy, hematopoietic cell transplantation, and/or radiation. Chicago (IL): American Academy of Pediatric Dentistry; 2004. 6 p. [24 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2004

GUIDELINE DEVELOPER(S)

American Academy of Pediatric Dentistry - Professional Association

SOURCE(S) OF FUNDING

American Academy of Pediatric Dentistry

GUIDELINE COMMITTEE

Clinical Affairs Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Not stated

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available from the [American Academy of Pediatric Dentistry Web site](#).

Print copies: Available from the American Academy of Pediatric Dentistry, 211 East Chicago Avenue, Suite 700, Chicago, Illinois 60611

AVAILABILITY OF COMPANION DOCUMENTS

Information about the American Academy of Pediatric Dentistry (AAPD) mission and guideline development process is available on the [AAPD Web site](#).

The following implementation tools are available for download from the AAPD Web site:

- [Dental growth and development chart](#)
- [American Academy of Pediatric Dentistry Caries-Risk Assessment Tool \(CAT\)](#)

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on March 16, 2005. The information was verified by the guideline developer on April 18, 2005.

COPYRIGHT STATEMENT

This summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and

related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 11/3/2008

